Janux Therapeutics Inc JANX

$17.83 -0.22 (-1.22%)

Valuation

Market cap
1,103,523,000
Revenue TTM
$10,000,000
Net income TTM
$-113,630,000
PE ratio
0.00
Forward PE
—
Profit margin
-1,136.30%
Debt to equity
0.00

Trading

Volume
905,800
Avg volume
883,860
Day's range
$17.70 – $18.62
Shares out
61,137,000
Stochastic %K
66%
Beta
2.40
Analysts
Strong Sell
Price target
$30.94

Price

Company profile

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical tri...

Show more

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. It also develops JANX011, a CD19-targeted adaptive immune response modulator that is in phase 1 clinical study developed for autoimmune diseases. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates; and Bristol Myers Squibb to develop and commercialize an undisclosed, novel tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Industry
Biotechnology
Sector
Healthcare
Phone
858 751 4493
Website
https://www.januxrx.com
Address
10955 Vista Sorrento Parkway, Suite 200, San Diego, United States

Latest news

Stocktwits

Bananya Oct 27, 1:57 PM
$JANX https://finance.yahoo.com/healthcare/articles/artiva-biotherapeutics-announces-strategic-discontinues-113000223.html
1 replies
metalcook Oct 14, 6:10 PM
$VIR The Vir deal is ~2x the total potential value of $JANX - $BMY , with ~2–3x the near-term cash/equity, covers three candidates instead of one, and includes an equity stake. Both are similar preclinical/masked-TCE platform deals for solid tumors in which the biotech does early work and the big pharma takes over later. Vir’s is a stronger platform validation on headline economics. Similar early-stage oncology/TCE or masking-tech deals often fall in the $500M–$1B+ range for 1–few programs; Vir’s sits at the higher end.
1 replies
MultipleCashMachine Oct 9, 8:53 AM
$JANX let’s go bby
0 replies
QuantGalaxy Oct 2, 2:33 PM
$JANX Wow only 1100 puts traded today? What’s the number at the end of the day?
1 replies
Merlintrader Sep 26, 9:25 AM
Prostate cancer: where can four approaches improve care? $BNTX, $CADL, $JANX, $TLX https://www.merlintrader.com/prostate-cancer-four-approaches-bntx-cadl-janx-tlx/
0 replies
MarketWarfare Sep 24, 2:13 PM
$JANX trading below cash again. Fuck You David Campbell. May you burn in hell.
0 replies
MarketWarfare Sep 15, 8:02 PM
$JANX absolutely torn apart. CEO David Campbell looking at his bank account and then looking at the share price, knowing he didn't do a damn thing to earn his millions.
0 replies
JFais Sep 14, 12:20 PM
$JANX (NP) ~$100M EV, first patient dosed with PSMA CD28-costim bispecific (goal of enhancing durability of responses) @JoseRestonVA $JNJ moving its CD28 PSMA into phase 3 along with KLK2/CD3 re validation Will be interested to see how double-masked JANX014 shapes up vs $VIR (the former seems very far behind)
0 replies